Vesanoid

Tretinoin (Vesanoid) soft capsules are oval, bicoloured, orange-yellow and reddish-brown.
Each capsule contains: Tretinoin 10 mg.
Excipients/Inactive Ingredients: Capsule contents: Soya bean oil 146.32 mg, yellow beeswax.
Capsule shell: Sorbitol (as part of Karion) ≤2.94 mg, gelatin, glycerol, karion (sorbitol, mannitol, starch [maize]), titanium dioxide, iron oxide yellow, iron oxide red.

Antineoplastic.
Pharmacology: Pharmacodynamics: Tretinoin is a natural metabolite of retinol and belongs to the class of retinoids, comprising natural and synthetic analogues.
Mechanism of action: According to FAB (French-American-British) classification of haematological disease, acute promyelocytic leukaemia (APL) is classified as M3 and M3v form of acute myeloid leukaemia (AML).
The mechanism of action of tretinoin in APL is not entirely known, and may be linked to specific binding of tretinoin to a nuclear retinoic acid receptor (RAR) given that the nuclear receptor alpha of retinoic acid (RARa) is altered in APL patients by fusion with a protein called PML. Pharmacological doses of tretinoin induce proteolytic degradation of the PML/RARa chimeric protein, hallmark of APL. Transcriptome analyses suggest that tretinoin may clear PML/RARa from promoters, thereby restoring the wild-type RARa function and releasing the differentiation block.
Pharmacodynamic effects: In vitro studies with tretinoin have demonstrated induction of differentiation and inhibition of cell proliferation in transformed haemopoietic cell lines, including human myeloid leukaemia cell lines.
Clinical efficacy and safety: In patients suffering from acute promyelocytic leukaemia (APL), tretinoin in combination with cytotoxic chemotherapy or with arsenic trioxide inhibits proliferation and induces the differentiation of promyelocytic blasts. With such combination treatment approach high rates of complete remission and low relapse rates can be achieved.
Tretinoin combined with cytotoxic chemotherapy: The combination of tretinoin with anthracycline chemotherapeutics has been investigated in various clinical trials with children, adults, and elderly APL patients. One of the internationally established and accepted treatment regimens is the AIDA2000 protocol. In this regimen, newly diagnosed patients were treated for induction therapy with 45 mg/m²/day tretinoin until complete remission, for a maximum of 45 days.
This was followed by 3 courses of consolidation therapy with a treatment for 15 days with an equal dose in each course. During maintenance therapy, tretinoin was administered every 3 months for 15 days for 2 years. According to their relapse risk, patients received a different regimen of chemotherapy. Using this treatment approach, a 6-year overall survival of 87.4%, and a 6-year disease-free survival of 85.6% was achieved. These data are in line with other larger clinical trials (LPA99 and LPA2005, APL2000, AMLCG2009) with complete remission rates of ≥90%, overall survival of 82 to 94%, and disease-free survival (DFS) of 82 to 90%.
Tretinoin combined with arsenic trioxide: The combination of tretinoin with arsenic trioxide has been investigated in the APL0406 clinical trial. In this prospective, randomised, multicentre, open-label, phase III non-inferiority trial, 276 newly diagnosed patients (adults between 18 to 71 years of age) with non-high-risk APL were randomly assigned to receive tretinoin/arsenic trioxide (ATO) or tretinoin/ chemotherapy. Complete remission was achieved in 100% in the tretinoin/arsenic trioxide arm and 97% in the tretinoin/chemotherapy arm, respectively. After a median follow-up of 40.6 months, the event-free survival, cumulative incidence of relapse, and overall survival at 50 months for patients in the tretinoin/arsenic trioxide versus tretinoin/chemotherapy arms were 97.3% vs. 80%, 1.9% vs. 13.9%, and 99.2% vs. 92.6%, respectively (P <0.001, P=0.0013, and P=0.0073, respectively). Concerning the safety profiles of treatment regimen, for patients receiving tretinoin/arsenic trioxide, adverse effects mainly consisted of frequent increase of liver enzymes, QTc prolongation, and hyperleukocytosis. In almost all patients, this toxicity was reversible and manageable with temporary drug interruption and dose adjustments as per protocol recommendations, including the addition of hydroxyurea.
Special populations: Children: In children, the treatment combining tretinoin with chemotherapy gives comparable results as with adults. For example, compared to data from adults in the APL93 trial 576 patients with 31 newly diagnosed children (5%) were investigated and no difference between adults and children was seen for complete remission rate, 5-year relapse rate, event free survival, and overall survival, but significantly better survival was seen in children after adjustment on white blood cell counts and incidence of microgranular M3 variant of APL.
In terms of toxicity and compared to adults, a higher frequency of pseudotumour cerebri has been observed in children and adolescents. The incidence decreases with the use of lower dose of tretinoin.
There are only limited data concerning the use of tretinoin in combination with arsenic trioxide in paediatric population.
Elderly: APL is less frequently diagnosed in the elderly (patients above 60 years). Elderly patients seem at least as responsive to therapy as do younger patients, but rates of response and survival are lower in this age setting owing to a higher incidence of early deaths and deaths in remission when conventional treatment with tretinoin and chemotherapy is used. The higher rate of early deaths in this cohort is due to greater comorbidities compared to those of younger patients. There are only limited data concerning the use of tretinoin in combination with arsenic trioxide in elderly population.
Pharmacokinetics: Tretinoin is an endogenous metabolite of vitamin A and is normally present in plasma.
Absorption: Oral doses of tretinoin are well absorbed and maximum plasma concentrations in healthy volunteers are attained after 3 hours. There is a large inter-patient and intra-patient variation in absorption of tretinoin.
Distribution: In plasma, tretinoin is extensively bound to plasma proteins. Following peak levels, plasma concentrations decline with a mean elimination half-life of 0.7 hours. Plasma concentrations return to endogenous levels following a single 40 mg dose after 7 to 12 hours. No accumulation is seen after multiple doses and tretinoin is not retained in body tissues.
Biotransformation: During continuous administration, a marked decrease in plasma concentration can occur, possibly due to cytochrome P450 enzyme induction which increases clearance and decreases bioavailability after oral doses.
Tretinoin is metabolised by CYP26A1 besides CYP3A4. Compounds that inhibit CYP26A1, such as ketoconazole, could result in an increase of tretinoin exposure. Clinical evidence is still lacking on the relative involvement of this enzyme to the overall metabolism of tretinoin.
Elimination: Renal excretion of metabolites formed by oxidation and glucuronidation is a major route (60 %) of elimination, while 30% is excreted in the faeces. Tretinoin is isomerised to 13-cis retinoic acid and oxidised to 4-oxo-metabolites. These metabolites have longer half-lives than tretinoin and may show some accumulation.
Renal and hepatic impairment: The requirement for dosage adjustment in patients with kidney or liver dysfunction has not been investigated. As a precautionary measure, the dose will be decreased to 25 mg/m²/day (see Dosage & Administration).

Tretinoin (Vesanoid) is indicated in combination with arsenic trioxide or chemotherapy for treatment of patients with acute promyelocytic leukaemia (APL) which is newly diagnosed, relapsed or refractory to chemotherapy (see Pharmacology: Pharmacodynamics under Actions and Dosage & Administration).
Treatment regimens: Combination of tretinoin with chemotherapy or arsenic trioxide is known to be effective and to induce very high rates of haematologic remission in patients with genetically confirmed APL, i.e. patients whose blasts harbour the t(15;17) by karyotyping or FISH or the PML-RARa fusion as detected by PCR. Thus, genetic confirmation of diagnosis is mandatory. Combination treatment with arsenic trioxide has been shown an effective treatment option in patients with newly diagnosed low-to-intermediate risk APL. However, because APL is characterised by high risk of early haemorrhagic death, current recommendations dictate that early treatment with tretinoin is started as soon as possible upon morphologic suspicion only.
For the selection of treatment strategy, the relapse risk indicated by pre-therapeutic white blood cell count (WBC) and platelet count (Sanz score) with high-risk (WBC >10 x 10⁹/L), intermediate risk (WBC ≤10 x 10⁹/L, platelet count ≤40 x 10⁹/L), and low risk (WBC ≤10 x 10⁹/L, platelet count >40 x 10⁹/L) should be taken into consideration.

Dosage: For all therapy phases, a total daily dose of 45 mg/m² body surface divided into two equal doses is recommended for oral administration to adult and elderly APL patients. This is approximately 8 capsules per patient per day (one capsule contains 10 mg tretinoin).
Paediatric population: There is limited safety and efficacy information on the use of tretinoin in children. For children the same treatment regimen as for adults is applicable. The optimal paediatric dose of tretinoin has not yet been established. In an attempt to reduce tretinoin related toxicity, the daily dose administered in children can be reduced to 25 mg/m². Dose reduction should be particularly considered for children with toxicity symptoms, such as intractable headache.
High risk patients: For patients at high risk of disease relapse according to Sanz score (see Indications), a treatment option is the triple combination of tretinoin, arsenic trioxide and chemotherapy (anthracyclines) for induction, followed by consolidation with tretinoin and arsenic trioxide.
Patients with hyperleukocytosis: Patients with hyperleukocytosis (see Precautions) can receive additional chemotherapy at the very onset of induction treatment.
Patients with hepatic and/or renal impairment: Due to the limited information on patients with hepatic and/or renal insufficiency, the dose will be decreased to 25 mg/m² as a precautionary measure.
Dose delay, modification and re-initiation: In cases of severe differentiation syndrome (DS, see Precautions), temporary interruption of tretinoin therapy should be considered. Treatment with tretinoin may need to be withheld during the initial acute symptomatic period, but may be resumed when symptoms resolve. If intracranial hypertension/pseudotumour cerebri occur, a reduction of tretinoin dose is recommended.
Method of administration: The capsules should be swallowed whole with water. They should not be chewed. It is recommended to take the capsules with a meal or shortly thereafter.
Induction therapy should be continued until complete remission has been achieved or up to a maximum of 90 days.
After completion of induction, consolidation therapy should be initiated with a tretinoin/ arsenic trioxide combination or with a tretinoin/ anthracycline-based chemotherapy regimen. As for induction therapy, the same tretinoin dose of 45 mg/m² body surface divided in two equal doses is recommended for oral administration during consolidation. Several cycles of consolidation therapy with tretinoin should be performed. Current guidelines recommend that tretinoin-free intervals are included after remission and during consolidation cycles.
If maintenance therapy is performed, tretinoin should be used at the same dose as for induction/consolidation therapy. As for consolidation therapy, in case of treatment with tretinoin for maintenance therapy treatment regimen should include drug-free intervals ("pulsed therapy"). If there has been a remission with tretinoin alone, it is not necessary to modify doses of tretinoin if tretinoin is used with chemotherapy.

In case of overdose with tretinoin, reversible signs of hypervitaminosis A (headache, nausea, vomiting, mucocutaneous symptoms) can appear.
The recommended dose in acute promyelocytic leukaemia is one quarter of the maximum tolerated dose in solid tumour patients (maximum dose: 195 mg/m²/day) and below the maximum tolerated dose in children (60 mg/m²/day).
There is no specific treatment in the case of an overdose; however, it is important that the patient be treated in a special haematological unit.

Tretinoin (Vesanoid) is contraindicated for use in patients with known hypersensitivity to tretinoin, other retinoids, soya, peanut or to any of the excipients listed in Description.
Tretinoin is teratogenic. It is therefore contraindicated in pregnancy and in nursing mothers, unless the benefit of tretinoin treatment outweighs the risks (see Use in Pregnancy & Lactation).
The use of tretinoin in combination with vitamin A, tetracyclines and retinoids is contraindicated (see Interactions).

Pregnancy: Tretinoin is teratogenic. Its use is contraindicated in pregnant women and women who might become pregnant during or within one month of the cessation of treatment, unless the benefit of tretinoin treatment outweighs the risk of foetal abnormalities due to the severity of the patient's condition and the urgency of treatment. There is an extremely high risk for any exposed foetus that a deformed infant will result if pregnancy occurs while taking tretinoin, irrespective of the dose or duration of the treatment. Therapy with tretinoin should only be started in female patients of child-bearing age if each of the following conditions is met: The patient is informed by the physician of the risks concerning pregnancy during and one month after treatment with tretinoin.
The patient is willing to comply with the mandatory contraception measures. It is absolutely essential that every woman of child-bearing potential who is to undergo treatment with tretinoin uses effective contraception during and for one month after discontinuation of treatment with tretinoin.
Pregnancy tests must be performed at monthly intervals during therapy.
In spite of these precautions, should pregnancy occur during treatment with tretinoin or up to one month after its discontinuation, there is a high risk of severe malformation of the foetus, particularly when tretinoin was given during the first trimester of pregnancy.

Tretinoin should be administered to patients with acute promyelocytic leukaemia only under the strict supervision of a physician who is experienced in the treatment of haematological/oncological diseases.
Supportive care appropriate for patients with acute promyelocytic leukaemia for example prophylaxis for bleeding and prompt therapy for infection, should be maintained during therapy with tretinoin. The patient's haematologic profile, coagulation profile, liver function test results, and triglyceride and cholesterol levels should be monitored frequently.
Supportive measures to counteract APL-associated coagulopathy include administration of platelets transfusion to maintain a platelet count >30-50 x 10⁹/L and fresh-frozen plasma or fibrinogen to maintain fibrinogen level >100-150 mg/dL. These values should be monitored daily and supportive care should continue during the entire induction phase until disappearance of clinical and laboratory signs of coagulopathy.
Differentiation syndrome/Retinoic acid syndrome: During clinical trials, hyperleukocytosis has been frequently observed, sometimes associated with the "retinoic acid syndrome" (RAS). RAS has been reported in many acute promyelocytic leukaemia patients treated with tretinoin (about 26% in some clinical trials) or in association with arsenic trioxide and may be fatal. RAS is now better defined as differentiation syndrome (DS).
DS is characterised by fever, dyspnoea, acute respiratory distress, pulmonary infiltrates, hypotension, pleural and pericardial effusions, peripheral oedema, weight gain, and may progress into pulmonary, hepatic, renal and multi-organ failure. Full-blown DS is a life-threatening condition. Early recognition and treatment of DS is therefore of paramount importance. Differentiation syndrome is frequently associated with hyperleukocytosis (see "Hyperleukocytosis").
An increased body mass index (BMI) has been identified as predictor factor for DS. Therefore, patients with increased BMI should be closely monitored during therapy especially in terms of respiratory functions, diuresis, and creatinine levels.
Treatment with dexamethasone (10 mg intravenous every 12 hours for a minimum of 3 days or until resolution of the symptoms) must be immediately initiated for patients who present early clinical signs of the syndrome.
In cases of severe DS, temporary interruption of tretinoin therapy should be considered.
Hyperleukocytosis: Patients experiencing hyperleukocytosis should be treated with full-dose anthracycline-based chemotherapy. Immediate treatment of patients with white blood cell (WBC) count of ≥5 x 10⁹/L at diagnosis or during any time of therapy is recommended.
In terms of combination therapy of tretinoin with arsenic trioxide, the use of hydroxyurea should be considered for treatment of leukocytosis to keep WBC <10.000/µL.
Pseudotumour cerebri: Tretinoin may cause intracranial hypertension/pseudotumour cerebri. Pseudotumour cerebri is a benign intracranial hypertension with cerebral oedema and absence of a tumour, clinically characterised by headache, papilloedema, diplopia, and possibly altered state of consciousness.
The concomitant use of other agents known to cause intracranial hypertension/pseudotumour cerebri might increase the risk of this condition (see Interactions).
If intracranial hypertension/pseudotumour cerebri occurs, dose reduction of tretinoin is recommended in addition to administration of diuretics (acetazolamide), corticosteroids and/or analgesics.
QTc prolongation: In connection with the combination therapy of tretinoin and arsenic trioxide, QTc prolongations were observed. This might lead to life-threatening torsade de pointes arrhythmias. For management of QTc prolongation an ECG monitoring prior and in the course of therapy, especially for patients with existing risk factors, is recommended.
Hepatotoxicity: Hepatotoxicity is increased with combination therapy of tretinoin and arsenic trioxide. The liver toxicity occurred predominantly during the first phase of therapy (induction therapy) and is mainly characterised by increase in transaminases. The observed hepatic damage is reversible with the suspension of arsenic trioxide and/or tretinoin.
Psychiatric disorders: Depression, depression aggravated, anxiety, and mood alterations have been reported in patients treated with systemic retinoids, including tretinoin. Particular care should be taken in patients with a history of depression. Patients should be monitored for signs of depression and referred for appropriate treatment if necessary. Awareness by family or friends may be useful to detect mental health deterioration.
Others: Cases of Sweet's syndrome or acute febrile neutrophilic dermatitis responded dramatically to corticosteroid treatment.
There is a risk of thrombosis (both venous and arterial) which may involve any organ system, during the first month of treatment (see Adverse Reactions). Therefore, caution should be exercised when treating patients with the combination of tretinoin and antifibrinolytic agents, such as tranexamic acid, aminocaproic acid or aprotinin (see Interactions).
Because hypercalcaemia may occur during therapy, serum calcium levels should be monitored.
The ability to drive or operate machinery might be impaired in patients treated with tretinoin, particularly if they are experiencing dizziness or severe headache.
Counselling for women of childbearing potential (see Use in Pregnancy & Lactation): Tretinoin is a retinoid and teratogenic effects were seen in humans with retinoid drugs. Consequently, therapy with tretinoin should only be started in a female patient of childbearing age if she is informed of the risks concerning pregnancy during a treatment with tretinoin. The patient should use a reliable contraception method and pregnancy tests must be performed before treatment and at monthly intervals during therapy.
Micro-dosed progestagene preparations ("minipill") are an inadequate method of contraception during treatment with tretinoin.
Tretinoin (Vesanoid) contains sorbitol; therefore, patients with rare hereditary problems of fructose intolerance should not take Tretinoin (Vesanoid).
Use in Children: Pseudotumour cerebri (see Adverse Reactions) has a higher incidence in paediatric patients than in adults. Clinical trial data show a decreased incidence of pseudotumour cerebri with the use of a lower tretinoin dose, without compromising the outcome results. Therefore, a dose reduction to 25 mg/m² should be considered for children with toxicity symptoms, such as intractable headache (see Dosage & Administration).

All the measures listed as follows and in Warnings should be considered in relationship to the severity of the disease and the urgency of the treatment.
Lactation: Nursing must be discontinued if therapy with tretinoin is initiated.

In patients treated with the recommended daily doses of tretinoin the most frequent undesirable effects are consistent with the signs and symptoms of the hypervitaminosis A syndrome, which tretinoin shares with other retinoids.
The adverse reactions listed in the table as follows have been reported in pivotal clinical studies and during the post-marketing period.
Adverse reactions are presented by MedDRA System Organ Class and frequency (very common (≥1/10)). Adverse reactions reported during the post-marketing period are also included in the table under the frequency category "not known" (cannot be estimated from the available data). (See table.)

Click on icon to see table/diagram/image

The decision to interrupt or continue therapy should be based on an evaluation of the benefit of the treatment versus the severity of the side-effects.
Description of selected adverse reactions: Differentiation syndrome (formerly known as retinoic acid syndrome) may be fatal and is characterised by fever, dyspnoea, acute respiratory distress, pulmonary infiltrates, pleural and pericardial effusions, hypotension, oedema, weight gain, hepatic, renal and multi-organ failure. Differentiation syndrome is frequently associated with hyperleukocytosis. For prevention and treatment of differentiation syndrome (see Precautions).
Leukocytosis/hyperleukocytosis are frequent adverse effects associated with tretinoin therapy of APL and may be accompanied by differentiation syndrome. However, most cases of leukocytosis/hyperleukocytosis are not associated with a differentiation syndrome.
In clinical trials increased frequencies of hyperleukocytosis, QTc prolongation and hepatotoxic effects have been observed with the combination therapy of tretinoin with arsenic trioxide compared to tretinoin/chemotherapy combination. Liver toxicity occurred predominantly during the first phase of therapy (induction therapy) and is mainly characterised by increase in transaminases. For the characteristics, prevention, and treatment of hyperleukocytosis, QTc prolongation and hepatotoxic effects (see Precautions).
Teratogenicity: See Use in Pregnancy & Lactation and Warnings.
Paediatric population: There is limited safety information on the use of tretinoin in children. There have been some reports of increased toxicity in children treated with tretinoin, particularly increased pseudotumour cerebri.

The effect of food on the bioavailability of tretinoin has not been characterised. Since the bioavailability of retinoids, as a class, is known to increase in the presence of food, it is recommended that tretinoin be administered with a meal or shortly thereafter.
As tretinoin is metabolised by the hepatic P450 system, there is the potential for alteration of pharmacokinetics parameters in patients administered concomitant medications that are also inducers or inhibitors of this system. Medications that generally induce hepatic P450 enzymes include rifampicin, glucocorticoids, phenobarbital and pentobarbital. Medications that generally inhibit hepatic P450 enzymes include ketoconazole, cimetidine, erythromycin, verapamil, diltiazem and ciclosporin. Increased toxicity of tretinoin (e.g. pseudotumour cerebri, hypercalcaemia) was reported when azole antifungals (e.g. fluconazole, voriconazole, posaconazole) were administered. This appears to be the result of a pharmacokinetic interaction mainly involving CYP3A4. Combination with other strong CYP3A4 inhibitors (protease inhibitors or macrolides, e.g. clarithromycin), may also trigger tretinoin toxicity. A dose reduction of tretinoin should be considered if necessary.
There are no data on a possible pharmacokinetic interaction between tretinoin and daunorubicin, idarubicin and cytarabine.
Antifibrinolytic agents such as tranexamic acid, aminocaproic acid and aprotinin: Cases of fatal thrombotic complications have been reported rarely in patients concomitantly treated with tretinoin and antifibrinolytic agents. Therefore, caution should be exercised when administering tretinoin concomitantly with these agents (see Precautions).
Agents known to cause intracranial hypertension/pseudotumour cerebri such as tetracyclines: Tretinoin may cause intracranial hypertension/pseudotumour cerebri. Concomitant administration of tretinoin and agents known to cause intracranial hypertension/pseudotumour cerebri as well might increase the risk of this condition (see Precautions).
Contraindicated drug associations (see Contraindications): Vitamin A: As the other retinoids, tretinoin must not be administered in combination with vitamin A because symptoms of hypervitaminosis A could be aggravated.

Use and handling: No special requirements.
Disposal: Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Bottles: Keep the bottle tightly closed; protect capsules from light, store at temperatures not exceeding 30°C.

Cytotoxic Chemotherapy

L01XF01 - tretinoin ; Belongs to the class of retinoids for cancer treatment. Used in the treatment of cancer.

Rx